| Outcome Measures: |
Primary: Pharmacokinetics parameters of INS068 and SHR20004: Cmax, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: AUC0-t, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: AUC0-inf, Based on pre-dose, 2-96 hours post-dose sampling times | Secondary: Pharmacokinetics parameters of INS068 and SHR20004: Tmax, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: T1/2, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: CL/F, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacokinetics parameters of INS068 and SHR20004: Vz/F, Based on pre-dose, 2-96 hours post-dose sampling times|Binding rate of plasma protein of INS068 in serum and SHR20004 in plasma(fu), Based on pre-dose, 2-96 hours post-dose sampling times|The incidence and severity of adverse events/serious adverse events, Based on pre-dose, 2-96 hours post-dose sampling times|Pharmacodynamic：Serum c-peptide, Based on pre-dose, 8-24 hours post-dose sampling times
|
